Nxera scraps 10% equity-pay cap as it grants executives options over up to 6.65mn shares
Nxera Pharma has withdrawn its 10% cap on share-based pay and will grant three executive officers options over up to 6.65mn shares, about 7.2% of shares outstanding, which vest only if price hurdles from ¥2,200 to ¥10,000 are met.